Viva Biotech (HKG:1873) expects an attributable profit of between 150 million yuan and 180 million yuan for the year 2024, against an attributable loss of 116.1 million yuan a year prior, a Thursday filing with the Hong Kong bourse said.
The biotechnology firm's adjusted non-IFRS attributable profit will fall between 240 million yuan and 270 million yuan for the year, mainly attributable to a substantial growth recovery of the contract research organization business, higher operating margins, and investment gains.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。